MetaTOC stay on top of your field, easily

Malignancy risk in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a 5-year population-based cohort study

, , ,

Therapeutic Advances in Musculoskeletal Disease

Published online on

Abstract

Therapeutic Advances in Musculoskeletal Disease, Volume 18, January-December 2026.
Background:Data regarding malignancy risk amongst rheumatoid arthritis (RA) patients using biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) was conflicting, and real-world Taiwanese data was lacking.Objectives:To ...